Lilly (Eli)

Eli Lilly and Company stands as one of the world's most innovative and valuable pharmaceutical companies, with a remarkable heritage spanning nearly 150 years since its founding in 1876. Headquartered in Indianapolis, Indiana, Lilly has grown from a small pharmaceutical chemist's operation into a global healthcare powerhouse operating in 18 countries with products sold in approximately 125 countries worldwide. In November 2025, the company achieved a historic milestone by becoming the first healthcare company to reach a $1 trillion market capitalization, cementing its position as the most valuable pharmaceutical company globally and ranking 11th among the largest biomedical companies by revenue.

The company's extraordinary recent success has been driven primarily by its breakthrough incretin medicines for diabetes and obesity. Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss and obstructive sleep apnea, accounted for 37% of 2024 revenues and has transformed treatment paradigms for millions of patients. In 2024, Mounjaro sales more than doubled to $11.54 billion, while Zepbound generated $4.9 billion in its first full year on the market following FDA approval in November 2023. The company's diverse portfolio also includes Verzenio for breast cancer (12% of revenues), Humalog insulin (5% of revenues), and the recently launched Alzheimer's treatment Kisunla, along with medicines for autoimmune diseases, cardiovascular conditions, and neurological disorders.

Lilly achieved exceptional financial performance in 2024 with total revenue of $45.04 billion, representing 32% growth from the prior year. The company's strong fundamentals are reflected in a gross margin of 83.2% and robust profitability, with Q4 2024 net income reaching $4.41 billion and earnings per share of $4.88. Looking ahead to 2025, Lilly has provided ambitious guidance projecting revenue between $58.0 billion and $61.0 billion, representing approximately 32% growth, demonstrating confidence in sustained momentum driven by its innovative pipeline and market-leading products.

With 47,000 employees globally, including 11,436 dedicated to research and development (22.8% of workforce), Eli Lilly maintains an unwavering commitment to scientific innovation and discovery. The company operates with core values of integrity, excellence, and respect for people, cultivating an inclusive culture that has increased women in management from 41% to over 49% and minority representation in U.S. management from 16% to nearly 25% between 2017 and 2022. Under the leadership of CEO David A. Ricks since 2017, Lilly continues to unite caring with discovery to make life better for people around the world, pursuing breakthrough medicines across oncology, immunology, neuroscience, cardiometabolic health, and other therapeutic areas while maintaining industry-leading sustainability commitments and environmental responsibility throughout its global operations.